Can medical imaging identify the histopathological growth patterns of liver metastases?


Journal

Seminars in cancer biology
ISSN: 1096-3650
Titre abrégé: Semin Cancer Biol
Pays: England
ID NLM: 9010218

Informations de publication

Date de publication:
06 2021
Historique:
received: 12 06 2020
revised: 29 06 2020
accepted: 06 07 2020
pubmed: 1 8 2020
medline: 4 3 2022
entrez: 1 8 2020
Statut: ppublish

Résumé

The histopathological growth patterns (HGPs) of liver metastases of colorectal cancer and of several other tumor types predict outcome of patients in multiple studies. The HGPs of liver metastases have a prognostic but also a predictive value with one of the growth patterns, the replacement growth pattern, related to resistance to systemic treatment. Given that the HGP can only be assessed in a reliable manner when a surgical resection of the metastasis has been performed, this biomarker cannot be exploited to the full. For example, HGPs can at this moment, not be used to decide whether patients with liver metastatic breast or colorectal cancer will benefit or not from locoregional treatment, such as surgery or radiotherapy, and from peri-operative systemic treatment. In this review we highlight studies that suggest that the HGPs of liver metastases can be identified by medical imaging. Although still to be confirmed by a prospective multicenter approach, some studies indeed achieve a high accuracy in predicting the HGPs by applying radiomic algorithms on CT- or MR-images of liver metastases. This is an important step towards a treatment planning of patients with liver metastatic cancer that takes into account the biology and the progression kinetics of the metastases.

Identifiants

pubmed: 32735852
pii: S1044-579X(20)30157-7
doi: 10.1016/j.semcancer.2020.07.002
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

33-41

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Emily Latacz (E)

Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium; Iridium Kankernetwerk, Antwerp, Belgium; Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium.

Pieter-Jan van Dam (PJ)

Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium; Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium; Histogenex, Antwerp, NV, Belgium.

Christian Vanhove (C)

Institute Biomedical Technology, Department Electronics and Information, Ghent University, Ghent, Belgium.

Laura Llado (L)

Tumor and Stromal Chemoresistance, Molecular Mechanisms and Experimental Therapeutics in Oncology program ONCOBELL, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; HBP and Liver Transplantation Unit, Department of Surgery, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Benedicte Descamps (B)

Institute Biomedical Technology, Department Electronics and Information, Ghent University, Ghent, Belgium.

Núria Ruiz (N)

Tumor and Stromal Chemoresistance, Molecular Mechanisms and Experimental Therapeutics in Oncology program ONCOBELL, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Ines Joye (I)

Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium; Iridium Kankernetwerk, Antwerp, Belgium; Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium.

Dirk Grünhagen (D)

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Steven Van Laere (S)

Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium; Iridium Kankernetwerk, Antwerp, Belgium; Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium.

Piet Dirix (P)

Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium; Iridium Kankernetwerk, Antwerp, Belgium; Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium.

David G Mollevi (DG)

Tumor and Stromal Chemoresistance, Molecular Mechanisms and Experimental Therapeutics in Oncology program ONCOBELL, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Program Against Cancer Therapeutic Resistance ProCure, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.

Cornelis Verhoef (C)

Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Luc Dirix (L)

Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium; Department of Oncological Research, GZA Hospital Sint-Augustinus, Antwerp, Belgium.

Peter Vermeulen (P)

Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium; Iridium Kankernetwerk, Antwerp, Belgium; Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium. Electronic address: peter.vermeulen@gza.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH